

# 台灣癌症登記中心通知

**急件**

發件人： 台灣癌症登記中心  
電話： 02-2341-6012  
傳真： 02-2351-1733  
地址： 100 台北郵政 84-310 信箱  
日期： 106 年 12 月 4 日  
編號： 癌登第 106005 號

收文者： 所有申報醫院

副本收文者： 衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主 題： 因應107年癌症登記實務作業之需求，請 貴院依說明段辦理

急件       請檢閱       請加註       請回覆       請回收

- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
- 二、 因應提升全國癌症登記申報時效性，自 107 年起醫院線上申報時程將提前一個月，即改為每 2、5、8、11 月份起開放申報。
- 三、 自 107 年起，所有診斷年度個案均全面採用下述 106 年修訂版申報。另 105 診斷年仍需申報個案，可沿用 105 年修訂版本申報，但必須於 106 年 12 月 31 日前依法完成申報。
- 四、 「100 年版台灣癌症登記摘錄手冊」- 106 年修訂版及「癌症部位特定因子 (SSF) 編碼手冊」- 106 年修訂版，業由各醫院惠示意見並依據專家會議討論後修訂完竣，修訂版之附錄修訂處有詳細更新說明，提供醫院參考。完整修訂版檔案請逕至台灣癌症登記中心網站下載，網址如下：  
<http://tcr.cph.ntu.edu.tw/main.php?Page=A6>。
- 五、 「100 年版台灣癌症登記摘錄手冊」與「癌症部位特定因子 (SSF) 編碼手冊」- 106 年修訂版重要修正摘要如下，詳細內容請參考 106 年修訂版手冊：
  - (1) 其他分期系統期別(臨床)(癌登欄位序號#3.19): 修改 DRE 編碼欄位 TX 之定義，“無法評估”改為“無肛、術後確診或其他因素無法執行 DRE”。
  - (2) 原發部位手術邊緣(癌登欄位序號#4.1.5): 新增編碼指引第六點：攝護腺癌個案僅接受 TURP(術式編碼為 21-23)，本欄位應編碼為 8。原第六點移至第七點。
  - (3) 放射治療儀器(癌登欄位序號#4.2.1.2)、體外放射治療技術(癌登欄位序號#4.2.2.1)、其他放射治療技術(癌登欄位序號#4.2.3.2): 修改編碼指引：若治療儀器描述為 SBRT (Stereotatic Body Radiotherapy) 或 SABR (Stereotatic Ablative Body Radiotherapy)，且治療技術使用諾力刀(Norvalis)、強度調控放射治療(IMRT)、體積弧形放射治療(Rapid Arc®)或質子(Proton)時，依據治療次數(Fraction / Session)及劑量區分

放射手術或體外放射治療：治療次數 $\leq 6$ 且劑量 $\geq 800$  cGy/次視為放射手術；治療次數 $>6$ 次或劑量 $< 800$  cGy/次，則登錄為體外放射線治療。

- (4) 其他放射治療技術(癌登欄位序號#4.2.3.2)：新增放射手術專用編碼欄位 6 及定義：放射手術只用立體定位質子治療。
- (5) 死亡原因(癌登欄位序號#5.6)：修正編碼指引第四點：若致死癌症為多發癌症，且無法確認死於其中何種癌症時，請編碼 C97 (Malignant neoplasms of independent (primary) multiple sites)。
- (6) 新增附錄 F：癌登中心通知文重要公告事項摘錄。
- (7) 食道癌 SSF1 正子掃描電腦斷層檢查：刪除編碼欄位 010、011 之定義及新增 020、030、040 之定義：

編碼	定義
000	無使用正子掃描電腦斷層檢查。
010	<del>有使用正子掃描電腦斷層檢查。</del>
011	<del>使用正子掃描(PET, 非 PET-CT 正子掃描電腦斷層)檢查。</del>
020	僅首次治療前有使用正子掃描電腦斷層檢查。
030	僅首次治療後有使用正子掃描電腦斷層檢查。
040	首次治療前後均有使用正子掃描電腦斷層檢查。

- (8) **胃癌** SSF1-5 新增不適用組織型態編碼：NETs (ICD-O-3 M-8153, 8240-8242, 8246, 8249)；且**新增收錄欄位 SSF 4：病理切片中的腫瘤深度、SSF 5：淋巴管或血管侵犯。**
- (9) **肺癌**新增收錄欄位 **SSF 7：ALK 基因轉位突變。**
- (10) 乳癌 SSF1,2,7 新增不適用組織型態編碼：Phyllodes tumors (ICD-O-3 M-9020)。
- (11) 攝護腺癌 SSF1 攝護腺特異抗原指數新增編碼指引：**個案分類為 0-2 者**，均須記載攝護腺特異抗原指數(PSA)最高值。

六、依據最新 WHO Classification of Head and Neck Tumours (2017)、WHO Classification of Tumours of Endocrine Organs (2017)彙整而成，因 2000 年出版之 ICD-O-3 編碼不敷使用，且現行病理報告按最新組織型態記載，故提供最新病理組織型態編碼供醫院使用(附件更新自癌登 105001 號通知文內容)，**WHO 2017 年新增編碼請於 2017 診斷年個案開始使用**。注意事項如下：

- (1) 胰臟的內分泌腫瘤：Insulinoma、Glucagonoma、Gastrinoma、Somatostatinoma、VIPoma、ACTH-producing tumour (C25.\_)，與 Pheochromocytoma (C74.1)、Carotid body paraganglioma (C75.4)、Middle ear paraganglioma (C75.5)，以及 Epithelioid hemangioendothelioma (C30.0, C31.\_)，自 106 診斷年起皆視為惡性，需申報。
- (2) Sellar ependymoma (C75.1)與 Immature teratoma (grade 2) (C73.9) 自 106 診斷年起應視為良性，不需申報；但 Malignant teratoma (grade 3) (C73.9) 仍應申報。

- 
- (3) Chondrosarcoma, NOS 與 Chondrosarcoma, grade 2/3 編碼為 9220/3 需申報；新增 Chondrosarcoma, grade 1 編碼為 9222/1，不需申報。
- (4) 新增編碼 Squamous cell carcinoma, HPV-positive 8085/3 與 Squamous cell carcinoma, HPV-negative 8086/3 (C01.9, C02.4, C05.1, C05.2, C09.\_, C10.\_)。

七、**再次提醒**：最新 AJCC Cancer Staging Manual 8th Edition 已於 2016 年底公布，將適用於 2018 年 1 月 1 日起新診斷之癌症個案，並於 2019 年 (民國 108 年)起開始申報。有關 AJCC 第八版最新內容或勘誤表，請參閱下列網址：

<https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx>

台灣癌症登記中心  
Taiwan Cancer Registry

Status	ICD-O-3	Term
New term	8020/3	Poorly differentiated urothelial carcinoma (C65.9, C66.9, C67.~, C68.~)
New term	8020/3	<b>Anaplastic thyroid carcinoma (C73.9)</b>
New code and term	<b>8023/3</b>	<b>NUT carcinoma (C34.~, C37.9)</b>
New term	8044/3	Small cell carcinoma, hypercalcaemic type (C56.9)
New code and term	<b>8054/3</b>	<b>Warty carcinoma (C60.~) [originally 8051/3]</b>
New behavior code and term	8071/2	<b>Differentiated-type vulvar intraepithelial neoplasia (C51.~)</b> <b>Differentiated penile intraepithelial neoplasia (C60.~)</b>
New term	8077/2	<b>Penile</b> intraepithelial neoplasia (C60.~)
New term	8077/2	Oral epithelial dysplasia, high grade (C00.~, C02.~, C03.~, C04.~, C05.~, C06.~)
New code and term	<b>8085/3</b>	<b>Squamous cell carcinoma, HPV-positive (C01.9, C02.4, C05.1, C05.2, C09.~, C10.~)</b>
New code and term	<b>8086/3</b>	<b>Squamous cell carcinoma, HPV-negative (C01.9, C02.4, C05.1, C05.2, C09.~, C10.~)</b>
New term	8140/3	Parathyroid carcinoma (C75.0)
New term	8140/3	<b>Endolymphatic sac tumor (C30.1)</b>
New term	8144/3	Enteric adenocarcinoma (C34.~)
Behavior code change (0→3)	<b>8151/3</b>	<b>Insulinoma (C25.~)</b>
Behavior code change (1→3)	<b>8152/3</b>	<b>Glucagonoma (C25.~)</b>
Behavior code change (1→3)	<b>8153/3</b>	<b>Gastrinoma (C25.~)</b>
New term	8154/3	Mixed ductal- <b>neuro</b> endocrine carcinomas (C25.~)
New term	8154/3	Mixed acinar- <b>neuro</b> endocrine carcinomas (C25.~)
Behavior code change (1→3)	<b>8155/3</b>	<b>VIPoma (C25.~)</b>
Behavior code change (1→3)	<b>8156/3</b>	<b>Somatostatinoma (C25.~)</b>
Behavior code change (1→3)	<b>8158/3</b>	<b>ACTH-producing tumour (C25.~)</b>
New term	8200/3	<b>Thymic carcinoma</b> with adenoid cystic carcinoma-like features (C37.9)
New term	8241/3	Serotonin-producing <b>tumour</b> (C25.~)
New behavior code and term	8250/2	<b>Adenocarcinoma in situ, non-mucinous (C34.~)</b>
New term	8250/3	<b>Lepidic</b> adenocarcinoma (C34.~)
New behavior code and term	8253/2	<b>Adenocarcinoma in situ, mucinous (C34.~)</b>

Status	ICD-O-3	Term
New term	8253/3	<b>Invasive</b> mucinous <b>adenocarcinoma (C34._)</b>
New term	8254/3	Mixed <b>invasive</b> mucinous and non-mucinous <b>adenocarcinoma (C34._)</b>
New code and term	<b>8256/3</b>	<b>Minimally invasive adenocarcinoma, non-mucinous (C34._)</b>
New code and term	<b>8257/3</b>	<b>Minimally invasive adenocarcinoma, mucinous (C34._)</b>
New code and term	<b>8273/3</b>	<b>Pituitary blastoma (C75.1)</b>
New code and term	<b>8311/3</b>	<b>Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (C64.9)</b> <b>MIT family translocation renal cell carcinomas (C64.9)</b> <b>Succinate dehydrogenase-deficient renal carcinoma (C64.9)</b>
New term	8316/3	<b>Acquired</b> cystic <b>disease-associated</b> renal cell carcinoma ( <b>C64.9</b> ) <b>Tubulocystic</b> renal cell carcinoma ( <b>C64.9</b> )
<b>Behavior code change (3→1)</b>	<b>8323/1</b>	<b>Clear cell papillary renal cell carcinoma (C64.9) [MP/H 8255/3→8323/1]</b>
New term	8330/3	Follicular thyroid carcinoma (FTC), <b>widely invasive (C73.9)</b>
New term	8337/3	<b>Poorly differentiated thyroid</b> carcinoma (C73.9)
New code and term	<b>8339/3</b>	<b>Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C73.9)</b>
New term	8342/3	<b>Oncocytic variant</b> of papillary thyroid carcinoma (PTC) (C73.9)
New term	8345/3	Medullary <b>thyroid</b> carcinoma (C73.9)
New code and term	<b>8349/1</b>	<b>Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (C73.9) [nonreportable]</b>
New behavior code and term	8380/2	<b>Atypical hyperplasia / Endometrioid intraepithelial neoplasia (C54._)</b>
New term	8430/3	<b>Sclerosing</b> mucoepidermoid carcinoma <b>with eosinophilia (C73.9)</b>
New behavior code and term	8441/2	Serous <b>tubal intraepithelial</b> carcinoma ( <b>C57.0</b> )
New behavior code and term	8441/2	Serous <b>endometrial intraepithelial</b> carcinoma ( <b>C54._</b> )
New behavior code and term	8460/2	Serous <b>borderline tumour</b> - micropapillary variant ( <b>C56.9</b> )
New behavior code and term	8460/2	<b>Non-invasive low-grade</b> serous carcinoma ( <b>C56.9</b> )
New term	8460/3	<b>Low-grade</b> serous carcinoma ( <b>C48._, C57._</b> )
New term	8461/3	<b>High-grade</b> serous carcinoma ( <b>C48._, C57._</b> )
New code and term	<b>8474/3</b>	<b>Seromucinous carcinoma (C56.9)</b>
New term	8480/3	Mucinous <b>tubular and spindle cell</b> carcinoma ( <b>C64.9</b> )
New term	8500/3	<b>Adenocarcinoma of mammary gland type (C51._)</b>

Status	ICD-O-3	Term
New term	8502/3	Secretory carcinoma (C07., C08.)
New term	8504/2	Encapsulated papillary carcinoma (C50.)
New term	8504/3	Encapsulated papillary carcinoma with invasion (C50.)
New behavior code and term	8507/3	Invasive micropapillary carcinoma (C50.)
New code and term	8509/2	Solid papillary carcinoma in situ (C50.)
New code and term	8509/3	Solid papillary carcinoma invasive (C50.)
New term	8510/3	Renal medullary carcinoma (C64.9)
New code and term	8519/2	Pleomorphic lobular carcinoma in situ (C50.)
New term	8551/3	Acinar adenocarcinoma (C34.)
New term	8580/3	Metaplastic thymoma / Sclerosing thymoma (C37.9)
New term	8580/3	Ectopic thymoma (C73.9)
Behavior code change (1→3)	8581/3	Type A thymoma, including atypical variant (C37.9)
Behavior code change (1→3)	8582/3	Type AB thymoma (C37.9)
Behavior code change (1→3)	8583/3	Type B1 thymoma (C37.9)
Behavior code change (1→3)	8584/3	Type B2 thymoma (C37.9)
Behavior code change (1→3)	8585/3	Type B3 thymoma (C37.9)
New term	8589/3	Intrathyroid thymic carcinoma (C73.9)
Behavior code change (1→3)	8690/3	Middle ear paraganglioma (C75.5)
Behavior code change (1→3)	8692/3	Carotid body paraganglioma (C75.4)
New term	8693/3	Vagal paraganglioma (C75.5)
New term	8693/3	Laryngeal paraganglioma (C75.5)
New term	8693/3	Sympathetic paragangliomas (C75.5)
New term	8693/3	Composite paraganglioma (C75.5)
New term	8693/3	Paraganglioma (C73.9, C75.1)
Behavior code change (0→3)	8700/3	Pheochromocytoma (C74.1)
New term	8700/3	Composite pheochromocytoma (C74.1)
New code and term	8714/3	Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C34., C47., C49., C54.) Perivascular epithelioid cell tumour, malignant (C65.9, C66.9, C67., C68.)



Status	ICD-O-3	Term
New term	8815/3	Solitary fibrous tumor, <b>grade 3 (C70., C72.)</b>
New behavior code and term	8825/3	<b>Low-grade</b> myofibrilastic <b>sarcoma (C47., C49.)</b>
New behavior code and term	8825/3	Myofibroblastic <b>sarcoma</b>
<b>Behavior code change (3→1)</b>	<b>8832/1</b>	<b>Dermatofibrosarcoma protuberans (C47., C49.)</b>
New term	8832/3	<b>Fibrosarcomatous</b> dermatofibrosarcoma protuberans (C47., C49.)
<b>Behavior code change (3→1)</b>	<b>8833/1</b>	<b>Pigmented dermatofibrosarcoma protuberans (C47., C49.)</b>
New term	8840/3	<b>Low-grade fibromyxoid sarcoma (C47., C49.)</b> <b>Sclerosing epithelioid fibrosarcoma (C47., C49.)</b>
New behavior code and term	8842/3	<b>Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation (C34.)</b> <b>Ossifying fibromyxoid tumour, malignant (C47., C49.)</b>
New term	8936/3	<b>Extra-gastrointestinal stromal tumour (C48.)</b>
New term	8963/3	<b>Extra-renal rhabdoid tumour (C47., C49.)</b>
New behavior code and term	8983/3	Adenomyoepithelioma <b>with carcinoma (C50.)</b>
New code and term	<b>9045/3</b>	<b>Biphenotypic sinonasal sarcoma (C30.0, C31.)</b>
<b>Behavior code change (3→1)</b>	<b>9080/1</b>	<b>Immature teratoma (grade 2) (C73.9)</b>
New term	9081/3	Teratocarcinosarcoma (C30.0, C31.)
New term	9084/3	<b>Germ cell tumours with sometic-type solid malignancy (C37.9)</b>
New code and term	<b>9086/3</b>	<b>Germ cell tumours with associated haematological malignancy (C37.9)</b>
<b>Behavior code change (1→3)</b>	<b>9133/3</b>	<b>Epithelioid hemangioendothelioma (C30.0, C31.)</b>
New code and term	<b>9137/3</b>	<b>Pulmonary artery intimal sarcoma (C34.)</b> <b>Intimal sarcoma (C47., C49.)</b>
New term	9180/3	<b>Extraskeletal osteosarcoma (C47., C49.)</b>
New term	9220/3	Chondrosarcoma, <b>grade 2/3 (C12.9, C13., C14., C32., C33.9, C41.0, C41.1)</b>
New code and term	<b>9222/1</b>	<b>Chondrosarcoma, grade 1 (C12.9, C13., C14., C32., C33.9, C41.0, C41.1)</b>
New term	9231/3	<b>Extraskeletal myxoid chondrosarcoma (C47., C49.)</b>
New term	9270/3	<b>Sclerosing odontogenic carcinoma (C41.0, C41.1)</b>
New behavior code and term	9302/3	Ghost cell odontogenic <b>carcinoma (C41.0, C41.1)</b>
New term	9330/3	<b>Odontogenic sarcomas (C41.0, C41.1)</b>

Status	ICD-O-3	Term
New behavior code and term	9341/3	Clear cell odontogenic <b>carcinoma</b> (C41.0, C41.1)
New code and term	<b>9385/3</b>	<b>Diffuse midline glioma, H3 K27M-mutant (C71._)</b>
New behavior code and term	9391/1	<b>Sellar <b>ependymoma (C75.1)</b> [nonreportable]</b>
New code and term	<b>9396/3</b>	<b>Ependymoma, RELA fusion-positive (C71._)</b>
New term	9424/3	<b>Anaplastic pleomorphic xanthoastrocytoma (C71._)</b>
New term	9440/3	Glioblastoma, <b>IDH-wildtype (C71._)</b>
New code and term	<b>9445/3</b>	<b>Glioblastoma, IDH-mutant (C71._)</b>
New term	9471/3	Medulloblastoma, <b>SHH-activated and TP53-wildtype (C71._)</b>
New term	9473/3	<b>CNS embryonal tumour, NOS (C71._)</b>
New code and term	<b>9475/3</b>	<b>Medulloblastoma, WNT-activated(C71._)</b>
New code and term	<b>9476/3</b>	<b>Medulloblastoma, SHH-activated and TP53-mutant (C71._)</b>
New code and term	<b>9477/3</b>	<b>Medulloblastoma, non-WNT/non-SHH (C71._)</b> <b>Medulloblastoma, group 3 / group 4 (C71._)</b>
New code and term	<b>9478/3</b>	<b>Embryonal tumour with multilayered rosettes, C19MC-altered (C71._)</b> <b>Embryonal tumour with multilayered rosettes, NOS (C71._)</b>
New term	9490/3	Ganglioneuroblastoma, <b>nodular (C74.1)</b>
New term	9490/3	Ganglioneuroblastoma, <b>intermixed (C74.1)</b>
New term	9508/3	<b>CNS embryonal tumour with rhabdoid features (C71._)</b>
New term	9540/3	<b>MPNST with perineurial differentiation (C72._)</b>
New code and term	<b>9542/3</b>	<b>Epithelioid malignant peripheral nerve sheath tumour (C47._, C49._)</b>

說明：綠色網底表示為本次新增編碼與修訂敘述。